Oslo, Norway, March 3, 2026 - Nykode Therapeutics ASA (OSE: NYKD), a
clinical-stage biopharmaceutical company dedicated to the discovery and
development of novel immunotherapies, today announces that it will play an
active role at the upcoming 9th Antigen Specific Immune Tolerance Summit (ASIT)
in Boston on March 3-5, 2026, with both an oral presentation, a scientific
poster, and participation in a panel discussion.

At the conference, Nykode will present new preclinical data further validating
its proprietary immunotherapy platform. The data demonstrate that selectively
targeting distinct antigen-presenting cell (APC) receptors can meaningfully
influence both the strength and the quality of immune responses. Importantly,
these findings have now been shown in murine models and in human cell systems.

These results support the core design of Nykode's technology, which is built to
precisely direct immune responses through APC targeting. The ability to tailor
the immune response to specific diseases has broad implications across oncology
and autoimmune disorders and reinforces the platform's versatility.

In addition to presenting new data, Nykode will contribute to a scientific panel
discussion, highlighting the company's thought leadership and active engagement
within the immune tolerance community.

"We are pleased to share additional data supporting the flexibility and power of
our platform and to contribute to the broader scientific dialogue in the field,"
said Agnete Fredriksen, CSO and Co-founder of Nykode Therapeutics.

Further details on presentation timing will be made available through the
conference program.


About Nykode Therapeutics
Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to
the discovery and development of novel immunotherapies with a focus on the
treatment of cancer and autoimmune diseases. Nykode's modular immunotherapy
technology specifically targets antigens to antigen presenting cells (APC),
which have been shown to induce a broad, strong and long-lasting antigen
specific immune response in cancer, which correlates with clinical responses.

Nykode's lead product candidates are abi-suva, a therapeutic immunotherapy for
the treatment of HPV16 induced malignancies which demonstrated favorable safety
and efficacy results from its Phase 2 trial for the treatment of late-line r/m
cervical cancer. Abi-suva is currently being further developed in head and neck
cancer. VB10.NEO, an individualized cancer neoantigen immunotherapy, has been
investigated in two trials with more than 10 different indications. 

Nykode is also utilizing its APC-targeted technology to create an immune
tolerance platform for the potential use in autoimmune disorders, organ
transplant rejections, anti-drug antibody reactions and allergy.

Nykode Therapeutics' shares are traded on the Oslo Stock Exchange (OSE: NYKD).
Further information about Nykode Therapeutics can be found at
http://www.nykode.com.


Forward-looking statements for Nykode Therapeutics
This announcement and any materials distributed in connection with this
announcement may contain certain forward-looking statements. By their nature,
forward-looking statements involve risk and uncertainty because they reflect the
company's current expectations and assumptions as to future events and
circumstances that may not prove accurate. A number of material factors could
cause actual results and developments to differ materially from those expressed
or implied by these forward-looking statements.

Contact for Nykode Therapeutics ASA:
IR@nykode.com

Nykode Therapeutics ASA
Oslo Science Park
Gaustadalléen 21
N-0349 Oslo, Norway